MetaCap

Cel-Sci (CVM) vs eXoZymes (EXOZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cel-Sci (CVM) has outperformed eXoZymes (EXOZ) over the past year, losing 80.7% versus a loss of 81.8%. eXoZymes is the larger company by market cap ($27.4 million vs $21.3 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CVM-80.67%EXOZ-81.84%
+28%-31%-90%
Nov 21, 20251 yearNov 20, 2026
CVM-92.80%EXOZ-73.88%
+90%-6%-103%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CVM versus EXOZ key metrics
MetricCVMEXOZ
Share price$1.21$2.91
Market cap$21.28M$27.42M
1-day change-17.69%-14.05%
YTD return-77.00%-73.35%
1-year return-80.67%-81.84%
5-year return-99.61%—
EPS (TTM)$-1.69$-1.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-25.41M$-9.16M
52-week high$7.80$16.16
52-week low$0.89$2.81
Distance from 52-week high-84.49%-82.02%
Analyst consensusnonestrong_buy
Avg. price target upside+933.06%—
Average volume231.46K10.14K
Shares outstanding17.59M9.44M
Employees—32
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cel-Sci

CVM stock →

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About eXoZymes

EXOZ stock →

eXoZymes, Inc. operates as a development stage biotechnology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees

CVM vs EXOZ FAQ

Which is bigger, Cel-Sci or eXoZymes?

eXoZymes (EXOZ) is larger, with a market capitalization of $27.42M compared with $21.28M for Cel-Sci (CVM).

Which stock has performed better over the past year, CVM or EXOZ?

CVM returned -80.67% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.

Are Cel-Sci and eXoZymes in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons